Oncolytics Biotech

Oncolytics Biotech is a clinical-stage immuno-oncology company developing pelareorep, a systemically delivered oncolytic reovirus, for solid tumors and hematologic malignancies. The company's lead program is in hormone-receptor-positive / HER2-negative breast cancer with ongoing pivotal trial preparations; pelareorep has shown clinical activity in multiple tumor types in combination with checkpoint inhibitors and chemotherapy. Oncolytics reported a corporate restructuring and auditor change in July 2026 (disengaging Ernst & Young and engaging Baker Tilly as the company's independent registered public accounting firm for the 2026 fiscal year, with prior reports containing a going-concern explanatory paragraph). The company is headquartered in San Diego, California and Calgary, Alberta, and trades on the Nasdaq Capital Market under the symbol ONCY.